* FTSE 100 down 0.6 pct
* FTSE 250 down 0.8 pct
* Global miners top drags
* Next rises after "respectable" Christmas update
* Sector M&A boosts AstraZeneca, GSK
(Adds company news items, analyst comment, updates share moves)
By Muvija M and Shashwat Awasthi
Jan 3 (Reuters) - UK shares ended a wobbly session in the red as weak U.S. factory data piled on worries over the world's economy that were triggered by smartphone giant Apple's rare revenue cut, taking the shine off a positive Christmas update from retailer Next.
Both indexes saw a small comeback around noon when pharmaceutical companies boosted the main index higher, after Bristol-Myers Squibb's BMY.N $74 billion purchase of Celgene CELG.O . giants AstraZeneca AZN.L and GlaxoSmithKline GSK.L recouped earlier losses and rose 1.8 percent and 0.4 percent respectively, while a resurgence in crude prices helped oil majors eke out gains.
But Apple's comments on "economic deceleration" in Greater China plus data showing that U.S. factory activity slowed more than expected in December ultimately had the final word.
Investors dumped stocks sensitive to China, the world's second-largest economy, and took refuge in gold, seen as a safe haven.
"What the market is wrestling with is whether it is indicative of a wider malaise in perhaps both the world economy and China," said Peter Rutter, head of global equities at Royal London Asset Management.
HSBC HSBA.L edged 0.8 percent lower and Standard Chartered (LON: STAN ) lost 3.2 percent, while luxury brand Burberry BRBY.L , also sensitive to signs of slowing demand in China, lost 6 percent to join the top fallers.
Blue-chip insurer Hiscox HSX.L dipped nearly 5 percent after hacker/hacking group "The Dark Overlord" claimed to have stolen 18,000 files from UK insurance firms involved in litigation for the 9/11 attacks in New York. MIXED BAG OF NEWS
One bright spot helping contain negative sentiment was high street clothing retailer Next NXT.L , which added 4.1 percent after reporting higher sales in the Christmas period thanks to a late surge in online demand. was indeed difficult for Next as well, but Christmas did arrive ultimately, with the last three weeks of December being very strong in sales terms," said Peel Hunt analysts, while Investec called it a respectable trading update.
Next's encouraging update also helped shares in Marks & Spencer MKS.L , Tesco TSCO.L , WM Morrison MRW.L and Primark-owner Associated British Foods ABF.L rise between 1.3 and 4.1 percent, among top blue-chip winners.
Prominent mid-cap and small-cap retailers, including Superdry SDRY.L , Dunelm DNLM.L , Debenhams DEB.L , rose. AIM-listed ASOS ASOS.L was up 5.7 percent, also boosted by Peel Hunt reinstating a "buy" rating on the online fashion store a month after its profit alert shook the global retail scene.
Still, investors continued to fret about the U.S.-China trade spat, a slowdown in the global economy, Brexit uncertainties, plunging oil prices - to name but a few.
Data showing growth in Britain's construction sector fell to a three-month low in December did little to help the mood, highlighting delays in commercial projects due to Britain's impending departure from the European Union. over how Britain would end up leaving the European Union has also restricted spending by companies and consumers alike, as a mid-January parliamentary vote on Prime Minister Theresa May's disputed EU divorce deal looms.
Brexit minister Stephen Barclay said Britain was more likely to end up leaving the European Union without a deal if parliament rejects May's agreement. of England Governor Mark Carney warned in November that a "no deal" scenario would be an economic shock akin to the 1970s oil crisis.
Industrial and bank shares were among the top drags on the mid-cap index, and only consumer staples and real estate stocks ended in black.
Among small-caps, drugmaker Vectura VEC.L soared 13 percent to lead the gainers after a positive trading update and AIM-listed Faroe Petroleum FPM.L rose 4.9 percent after DNO's DNO.OL takeover offer became mandatory. FTAS Consumer SVS vs FTAS
https://tmsnrt.rs/2ArF9im GSK, AZN rise after BMY-CELG deal
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.